title: Companies wager high on CD38-targeting drugs for blood cancer.
authors.forename: Rebecca
authors.initials: R
authors.lastname: Hersher
mesh_terms: D051997:ADP-ribosyl Cyclase 1 / Q000276:immunology* / Q000378:metabolism; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004345:Drug Industry; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D006801:Humans; D008562:Membrane Glycoproteins / Q000276:immunology* / Q000378:metabolism
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D008562:Membrane Glycoproteins; C556306:daratumumab; C498154:CD38 protein, human; D051997:ADP-ribosyl Cyclase 1